Filing Flows › Encompass Health (EHC) › Stock forecast & fair value
Encompass Health (EHC) stock forecast and fair value
Encompass Health (EHC) trades at $137.81. 12 analysts' median price target is $155.00 (+12%), from $142.00 to $177.00. Across 18 valuation methods the middle fair value is $60.65 (-56%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| P/E vs peers | $51.43 | $60.65 | $97.88 | -56% |
| P/E vs peers, weighted | $51.89 | $67.30 | $92.05 | -51% |
| P/E vs peers, matched | $105.00 | $161.93 | $193.60 | +18% |
| EV/Sales vs peers | $25.86 | $52.34 | $81.25 | -62% |
| EV/Sales vs peers, weighted | $22.29 | $46.29 | $81.58 | -66% |
| EV/Sales vs peers, matched | $31.91 | $70.02 | $118.46 | -49% |
| Residual income | $42.61 | $44.24 | $45.97 | -68% |
| Analysts' price targets | $142.00 | $156.08 | $177.00 | +13% |
| Owner earnings capitalized | $22.85 | $26.59 | $31.81 | -81% |
| Shareholder yield (dividends + buybacks) | $33.19 | $38.63 | $46.22 | -72% |
Encompass Health's latest quarter
Encompass Health, Q3 2026: revenue $1.6B (+9% year over year), operating margin 17.9%, net earnings $150M, operating cash flow $362M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for EHC stock?
The median of 12 analysts' 12-month targets is $155.00, +12% from $137.81; the range is $142.00 to $177.00. The average rating is strong buy.
What is Encompass Health's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $9.76 and $161.93, with a middle value of $60.65 against a price of $137.81. Each method's assumptions are on the page.
Does Encompass Health usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is EHC stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.